Fetus or Neonate Affected by Maternal Epidural Anesthesia During Labor and DeliveryNCT02565485
Pulse Pressure and Post-epidural Fetal Heart Rate Changes
A study testing Lactated Ringer's in people with Fetus or Neonate Affected by Maternal Epidural Anesthesia During Labor and Delivery, run by MetroHealth Medical Center at 1 site in United States.
Trial summary
Epidural anesthesia, the most common method of pain control in labor, can contribute to alterations in maternal blood pressure and/or fetal heart rate changes. As a result, the administration of an IV fluid bolus ("preload") is standard prior to epidural placement. Read more about this study
- Who is it for?
- Ages 18 to 50 years, women only
- Conditions the study is for
- Fetus or Neonate Affected by Maternal Epidural Anesthesia During Labor and Delivery
- What is being tested?
- Lactated Ringer's
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 276 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Sep 2015to 1 Nov 2016
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- Singleton pregnancy with gestational age ≥ 35 weeks
- Admission for delivery
- Age 18 or older
- Desires neuraxial analgesia in labor
- No exclusion criteria
- Maternal pulse pressure < 45 mmHg on admission (verified by repeat blood pressure)
- Category 1 FHT on admission/prior to epidural placement
- Epidural placement within 6 hours of admission to Labor and Delivery
Who cannot join
- Multiple gestation
- Intrauterine growth restriction
- Hypertensive disorders (gestational hypertension, chronic hypertension, and preeclampsia/eclampsia)
- Gestational or pregestational diabetes mellitus
- Substance abuse
- Intrauterine fetal demise
Show all 12Show fewer
- Congenital or chromosomal fetal abnormalities
- Category II or III FHR tracing on admission to L\&D (pre-epidural)
- Contraindication to neuraxial aesthesia (e.g. thrombocytopenia)
- Maternal cardiomyopathy, congenital heart disease, active pulmonary edema or any other underlying maternal cardiopulmonary condition that increases the risk of pulmonary edema
- Maternal renal insufficiency (serum creatinine > 1.0)
- Maternal hypotension (as defined in secondary outcomes below) prior to epidural placement
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Pulse Pressure-guided IV Fluid Preload to Prevent Post-epidural Fetal Heart Rate (FHR) Changes: a Randomized Controlled Trial
Epidural anesthesia, the most common method of pain control in labor, can contribute to alterations in maternal blood pressure and/or fetal heart rate changes. As a result, the administration of an IV fluid bolus ("preload") is standard prior to epidural placement. However, the optimal volume of preload is unknown and no clinical trials have evaluated a risk-factor based approach to dosing. Studies in the critical care, trauma, and obstetric literature have suggested that a narrow pulse pressure (difference between systolic and diastolic blood pressures) is a marker of reduced intravascular volume status and may identify women at a higher risk for new onset fetal heart rate changes after epidural placement. Therefore, the purpose of this study is to assess if an increased IV fluid preload bolus among women with a narrow pulse pressure reduces the risk of new onset fetal heart rate changes after epidural placement.
Read the detailed description
Objective:
To assess the efficacy of increased IV fluid preload for the prevention of post-epidural FHR changes in women with narrow pulse pressure
Hypothesis:
In individual with narrow pulse pressure, an increased IV fluid bolus will reduce the rate of post-epidural FHR changes.
Background:
In contemporary obstetric practice, regional anesthesia is the most commonly utilized method for pain management in labor. Compared with no anesthesia, neuraxial techniques have been associated with an increased risk of maternal hypotension, operative vaginal delivery, maternal fever, and cesarean delivery for fetal distress. Following the initial dosing of regional anesthesia, maternal hypotension and FHR abnormalities occur with reported frequencies of 5-18% and 6-30% respectively.
Neuraxial anesthesia can induce a sympathetic blockade, which results in decreased maternal systemic vascular resistance and venous return. These alterations in the maternal hemodynamic profile impact maternal blood pressure, uteroplacental blood flow and fetal perfusion, and may contribute to maternal hypotension and changes in the FHR after initiation of regional anesthesia. Importantly, these hemodynamic changes generally occur in the setting of a constant maternal intravascular volume. Given that the uteroplacental circulation has limited capacity for autoregulation, uterine perfusion is sensitive to changes in both maternal blood pressure and venous return. This physiology represents the basis for the administration of an intravenous (IV) bolus prior to or during the placement of regional anesthesia .
While maternal hypotension and FHR changes after neuraxial anesthesia are common occurrences, limited information on maternal and fetal characteristics or risk factors has been published. A recent retrospective cohort study by Miller et al. reported that a narrow maternal pulse pressure was a risk factor for post-epidural FHR changes. In this cohort study, women with an admission pulse pressure < 45, compared with pulse pressure > 45, had a marked increase in the risk of post-epidural FHR changes (27% vs 6%, p < 0.001, OR 5.6 [2.1-14.3], aOR 28.9 [3.8-221.4]). Interestingly, the incidence of maternal hypotension was not different between the two pulse pressure groups (21% vs 25%, p=0.49), suggesting that fetal perfusion is sensitive to the reduced venous return associated with increased venous capacitance related to reduced sympathetic tone. Further supporting this premise, a study by Vricella et al. demonstrated an increased rate of post-epidural maternal hypotension, vasopressor support and FHR changes in women with severe preeclampsia, a clinical state of volume contraction, compared with normotensive controls. The authors concluded that the vasoconstriction and intravascular depletion central to the syndrome of severe preeclampsia make this subset of women vulnerable to post-epidural hemodynamic changes and that administration of a standard IV fluid bolus may not adequately compensate for increased venous capacitance.
Data from the critical care and trauma literature further support the use of pulse pressure as a marker of hypovolemia. Conventional static indicators of cardiac preload, such as central venous pressure (CVP) or pulmonary capillary wedge pressure (PCWP), are poor predictors of "volume responsiveness", which is the cardiovascular response (i.e. changes in preload) to intravascular volume expansion with IV fluid. However, dynamic parameters such as variation in pulse pressure or stroke volume, are highly predictive of volume responsiveness. While data on pulse pressure variation are primarily derived from non-pregnant, mechanically ventilated individuals, a small case series demonstrated that pulse pressure variation accurately reflects volume responsiveness in pregnant women undergoing cesarean delivery under regional anesthesia. Additionally, data from the trauma literature have also demonstrated pulse pressure to represent an accurate surrogate of stroke volume and marker of central hypovolemia. Covertino et al. reported a direct relationship between pulse pressure and central volume reductions without any difference in mean arterial pressure. As such, pulse pressure may serve as a better maker of central hypovolemia than blood pressure alone. Therefore, pulse pressure may better predict low maternal intravascular volume and serve as a marker for post-epidural FHR changes.
Pregnancy itself is associated with alterations in blood pressure with decreased vascular tone and widening of the pulse pressure. Normal pulse pressure and variations in pregnancy are poorly described. However, in otherwise healthy non-pregnant adults, stroke volume is approximately 1.7 times the pulse pressure. Given that the stroke volume in a term pregnancy is approximated to be 100 mL/min, a normal pulse pressure in pregnancy should be approximately 60 mmHg. Therefore, a level of 45 mmHg has been proposed to define a low pulse pressure in pregnancy.
Notably, no prospective studies have evaluated a risk-factor based approach, namely the use of maternal volume status, to guide the volume of the IV fluid bolus administered prior to neuraxial anesthesia. The investigators hypothesize that in individuals with narrow pulse pressure, an increased IV fluid bolus will reduce the rate of post-epidural FHR changes. While pulse pressure variation has been best characterized as a marker of fluid responsiveness in previously healthy critically ill patients, this parameter is only readily obtained through use of an automated device (FloTrac/Vigileo system, Edwards Lifesciences, Irvine, CA) that requires an arterial line. Furthermore, pulse pressure variation has primarily been assessed in mechanically ventilated patients, which is rare in the obstetric setting. Therefore, based on the preliminary data by Miller et al., the investigators plan to use pulse pressure (and not pulse pressure variation) as a marker of intravascular volume this study with a cut point of 45 mmHg to define low pulse pressure. Given that previous studies have used IV fluid preload doses ranging from 500-1500 mL, the IV fluid dosing regimens that will be used in this study represent variations in the standard of care. A practical study design is proposed using current practice patterns for a low risk intervention in a low risk population.
Study Design:
Prospective Randomized Controlled Trial
Study Protocol:
Women meeting eligibility criteria will be recruited and randomized in a 1:1 ratio into two study groups: standard IV fluid bolus prior to epidural placement (500 mL Lactated Ringers) or "volume replacement" IV fluid bolus of 1500mL Lactated Ringers. IV fluid boluses will be infused over 30 minutes and administered within 1 hour of epidural placement. A third group will also be recruited as a control, which will include women with a pulse pressure > 45 on admission (and otherwise meet the aforementioned inclusion/exclusion criteria). The control group will receive the standard preload bolus of 500 mL prior to epidural placement.
This is a practical study using standard clinical practice methods to assess vital signs. Maternal vital signs (blood pressure, heart rate) will be collected in the left lateral recumbent position after an initial 5 minute period without activity. Automated devices will be used to assess blood pressure and pulse pressure at the following times: on admission, immediately prior to infusion of IV fluid bolus in preparation for epidural placement, immediately following IV fluid bolus infusion, at epidural test dose (T=0), every 5 minutes for 30 minutes (T=0 to T=30), and then every 10 minutes for the next 30 minutes (T=30 to T=60).
The chart will be abstracted to identify changes in the FHR and interventions. Continuous external (or internal, if placed for typical obstetric indications), fetal monitoring will be performed before and after epidural placement as is standard on our L\&D unit. Treatment of hypotension with administration of vasopressors or additional IV fluid boluses along with the treatment of FHR abnormalities (maternal position changes, supplemental oxygen administration, tocolytic use, cessation of oxytocin) will be recorded. Operative delivery for non-reassuring fetal status in the 60 minutes after epidural placement will be recorded. Additionally, maternal demographic and medical/obstetric data, maternal and neonatal delivery and outcome data will be recorded.
The technique for epidural placement and dosing will be standardized as follows. Epidural dosing will consist of 5 mL of 0.125% bupivicane with 10 mcg/mL of fentanyl. This standard bolus dose will be administered and levels of sensory block and numeric patient pain scores will be recorded. If patients have not achieved a pain score of 4 or less at 15 minutes after the epidural bolus, an additional bolus will be administered to achieve appropriate pain control. The volume of additional epidural bolus will be recorded.
Two independent obstetricians blinded to the randomization group and delivery outcome will interpret the FHR tracing for one hour before and after epidural placement. The FHR tracings will be divided into 15 minute epochs and categorized using the standard ACOG categories: I, II and III. Additional information including FHR baseline, FHR variability, and the presence or absence of accelerations or decelerations will be recorded for each 15min epoch. Discrepancies between the tracing interpretations will be reviewed by a third obstetrician for development of a consensus interpretation.
- Being tested
- Lactated Ringer's
- Keywords
- pulse pressure, fetal heart rate, epidural analgesia, hypotension, preload, fluid bolus, central hypovolemia
- Medical subject headings
- Hypotension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Lactated Ringer'sDrug
Also called Ringer's Lactate
1500 cc of IV Fluid (crystalloid) used for preload prior to epidural administration in the treatment arm. Control arm receives 500 cc.
| Study group | Role | What they receive |
|---|---|---|
| Standard IV Preload | No intervention | Patients in this arm will receive 500mL of Lactated Ringer's solution, which is the standard IV fluid preload used on Labor and Delivery at MetroHealth Medical Center |
| Volume Replacement IV Preload | Experimental | Patients in this arm will receive 1500mL of Lactated Ringer's solution Receives: Drug: Lactated Ringer's |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of New-onset Category II or III Fetal Heart Rate Tracings
Each fetal heart rate tracing was evaluated in 15 min increments from the completion of epidural placement and initial dose administration. ACOG Category I, II, and III was assigned to each 15 min increment.
Measured: First 60 minutes following epidural placement
Secondary outcomes (3)
New Onset Hypotension (>20% Decrease in Systolic and/or Diastolic Blood Pressure)
Measured: First 60 minutes following epidural placement
Interventions to Correct Maternal Hypotension or Fetal Heart Rate Abnormalities (Position Change, Supplemental Oxygen, Vasopressor Support, Emergent Operative Delivery)
Measured: First 60 minutes following epidural placement
Adverse Events (Pulmonary Edema)
Pulmonary edema occurring after preload bolus through delivery was considered an adverse event.
Measured: Duration of intrapartum course
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Oct 2015 (estimated)
- Study start1 Sep 2015
- Primary completion1 Nov 2016
- Study completion1 Nov 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (23)Papers the sponsor has linked to this study.
- Other trials for Fetus or Neonate Affected by Maternal Epidural Anesthesia During Labor and DeliveryStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 276 participants (actual)
Sponsor and investigators
- Lead sponsor
- MetroHealth Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Edward Chien, MD, MetroHealth Medical Center
- Investigators
- Justin R Lappen, MD, Principal investigator, MetroHealth Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02565485
- Sponsor's protocol ID
- IRB15-00366
- Status last verified
- Jun 2018
- First submitted
- 28 Sep 2015
- Last updated
- 9 Jul 2018
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Publications
Osterman MJ, Martin JA. Epidural and spinal anesthesia use during labor: 27-state reporting area, 2008. Natl Vital Stat Rep. 2011 Apr 6;59(5):1-13, 16.
PubMed 21553556Bucklin BA, Hawkins JL, Anderson JR, Ullrich FA. Obstetric anesthesia workforce survey: twenty-year update. Anesthesiology. 2005 Sep;103(3):645-53. doi: 10.1097/00000542-200509000-00030. No abstract available.
PubMed 16129992Anim-Somuah M, Smyth RM, Jones L. Epidural versus non-epidural or no analgesia in labour. Cochrane Database Syst Rev. 2011 Dec 7;(12):CD000331. doi: 10.1002/14651858.CD000331.pub3.
PubMed 22161362Collins KM, Bevan DR, Beard RW. Fluid loading to reduce abnormalities of fetal heart rate and maternal hypotension during epidural analgesia in labour. Br Med J. 1978 Nov 25;2(6150):1460-1. doi: 10.1136/bmj.2.6150.1460.
PubMed 719463Kinsella SM, Pirlet M, Mills MS, Tuckey JP, Thomas TA. Randomized study of intravenous fluid preload before epidural analgesia during labour. Br J Anaesth. 2000 Aug;85(2):311-3. doi: 10.1093/bja/85.2.311.
PubMed 10992845Kubli M, Shennan AH, Seed PT, O'Sullivan G. A randomised controlled trial of fluid pre-loading before low dose epidural analgesia for labour. Int J Obstet Anesth. 2003 Oct;12(4):256-60. doi: 10.1016/S0959-289X(03)00071-2.
PubMed 15321453Nielsen PE, Erickson JR, Abouleish EI, Perriatt S, Sheppard C. Fetal heart rate changes after intrathecal sufentanil or epidural bupivacaine for labor analgesia: incidence and clinical significance. Anesth Analg. 1996 Oct;83(4):742-6. doi: 10.1097/00000539-199610000-00014.
PubMed 8831313Paech MJ, Godkin R, Webster S. Complications of obstetric epidural analgesia and anaesthesia: a prospective analysis of 10,995 cases. Int J Obstet Anesth. 1998 Jan;7(1):5-11. doi: 10.1016/s0959-289x(98)80021-6.
PubMed 15321239Wolfler A, Salvo I, Sortino G, Bonati F, Izzo F. Epidural analgesia with ropivacaine and sufentanil is associated with transient fetal heart rate changes. Minerva Anestesiol. 2010 May;76(5):340-5.
PubMed 20395896Hofmeyr G, Cyna A, Middleton P. Prophylactic intravenous preloading for regional analgesia in labour. Cochrane Database Syst Rev. 2004 Oct 18;2004(4):CD000175. doi: 10.1002/14651858.CD000175.pub2.
PubMed 15494990Gaiser RR, McHugh M, Cheek TG, Gutsche BB. Predicting prolonged fetal heart rate deceleration following intrathecal fentanyl/bupivacaine. Int J Obstet Anesth. 2005 Jul;14(3):208-11. doi: 10.1016/j.ijoa.2004.12.010.
PubMed 15935647Nicolet J, Miller A, Kaufman I, Guertin MC, Deschamps A. Maternal factors implicated in fetal bradycardia after combined spinal epidural for labour pain. Eur J Anaesthesiol. 2008 Sep;25(9):721-5. doi: 10.1017/S0265021508004183. Epub 2008 Apr 10.
PubMed 18400139Miller NR, Cypher RL, Nielsen PE, Foglia LM. Maternal pulse pressure at admission is a risk factor for fetal heart rate changes after initial dosing of a labor epidural: a retrospective cohort study. Am J Obstet Gynecol. 2013 Oct;209(4):382.e1-8. doi: 10.1016/j.ajog.2013.05.049. Epub 2013 Jun 13.
PubMed 23769849Vricella LK, Louis JM, Mercer BM, Bolden N. Epidural-associated hypotension is more common among severely preeclamptic patients in labor. Am J Obstet Gynecol. 2012 Oct;207(4):335.e1-7. doi: 10.1016/j.ajog.2012.07.029.
PubMed 23021700Marik PE, Cavallazzi R, Vasu T, Hirani A. Dynamic changes in arterial waveform derived variables and fluid responsiveness in mechanically ventilated patients: a systematic review of the literature. Crit Care Med. 2009 Sep;37(9):2642-7. doi: 10.1097/CCM.0b013e3181a590da.
PubMed 19602972
Study at a glance
From the registry record, last updated by the sponsor on 9 Jul 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pulse Pressure-guided IV Fluid Preload to Prevent Post-epidural Fetal Heart Rate (FHR) Changes: a Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT02565485
- Acronym / sponsor ID
- IRB15-00366
- Keywords
- pulse pressure, fetal heart rate, epidural analgesia, hypotension, preload, fluid bolus, central hypovolemia
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 276 participants (actual)
- Lead sponsor
- MetroHealth Medical CenterUniversity, hospital or other
- Study start
- 1 Sep 2015 (actual)
- Primary completion
- 1 Nov 2016 (actual)
- Study completion
- 1 Nov 2016 (actual)
- First posted
- 1 Oct 2015 (estimated)
- Results
- Posted 8 Jun 2018
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Epidural anesthesia, the most common method of pain control in labor, can contribute to alterations in maternal blood pressure and/or fetal heart rate changes. As a result, the administration of an IV fluid bolus ("preload") is standard prior to epidural placement. However, the optimal volume of preload is unknown and no clinical trials have evaluated a risk-factor based approach to dosing. Studies in the critical care, trauma, and obstetric literature have suggested that a narrow pulse pressure (difference between systolic and diastolic blood pressures) is a marker of reduced intravascular volume status and may identify women at a higher risk for new onset fetal heart rate changes after epidural placement. Therefore, the purpose of this study is to assess if an increased IV fluid preload bolus among women with a narrow pulse pressure reduces the risk of new onset fetal heart rate changes after epidural placement.
Detailed description
Objective:
To assess the efficacy of increased IV fluid preload for the prevention of post-epidural FHR changes in women with narrow pulse pressure
Hypothesis:
In individual with narrow pulse pressure, an increased IV fluid bolus will reduce the rate of post-epidural FHR changes.
Background:
In contemporary obstetric practice, regional anesthesia is the most commonly utilized method for pain management in labor. Compared with no anesthesia, neuraxial techniques have been associated with an increased risk of maternal hypotension, operative vaginal delivery, maternal fever, and cesarean delivery for fetal distress. Following the initial dosing of regional anesthesia, maternal hypotension and FHR abnormalities occur with reported frequencies of 5-18% and 6-30% respectively.
Neuraxial anesthesia can induce a sympathetic blockade, which results in decreased maternal systemic vascular resistance and venous return. These alterations in the maternal hemodynamic profile impact maternal blood pressure, uteroplacental blood flow and fetal perfusion, and may contribute to maternal hypotension and changes in the FHR after initiation of regional anesthesia. Importantly, these hemodynamic changes generally occur in the setting of a constant maternal intravascular volume. Given that the uteroplacental circulation has limited capacity for autoregulation, uterine perfusion is sensitive to changes in both maternal blood pressure and venous return. This physiology represents the basis for the administration of an intravenous (IV) bolus prior to or during the placement of regional anesthesia .
While maternal hypotension and FHR changes after neuraxial anesthesia are common occurrences, limited information on maternal and fetal characteristics or risk factors has been published. A recent retrospective cohort study by Miller et al. reported that a narrow maternal pulse pressure was a risk factor for post-epidural FHR changes. In this cohort study, women with an admission pulse pressure < 45, compared with pulse pressure > 45, had a marked increase in the risk of post-epidural FHR changes (27% vs 6%, p < 0.001, OR 5.6 [2.1-14.3], aOR 28.9 [3.8-221.4]). Interestingly, the incidence of maternal hypotension was not different between the two pulse pressure groups (21% vs 25%, p=0.49), suggesting that fetal perfusion is sensitive to the reduced venous return associated with increased venous capacitance related to reduced sympathetic tone. Further supporting this premise, a study by Vricella et al. demonstrated an increased rate of post-epidural maternal hypotension, vasopressor support and FHR changes in women with severe preeclampsia, a clinical state of volume contraction, compared with normotensive controls. The authors concluded that the vasoconstriction and intravascular depletion central to the syndrome of severe preeclampsia make this subset of women vulnerable to post-epidural hemodynamic changes and that administration of a standard IV fluid bolus may not adequately compensate for increased venous capacitance.
Data from the critical care and trauma literature further support the use of pulse pressure as a marker of hypovolemia. Conventional static indicators of cardiac preload, such as central venous pressure (CVP) or pulmonary capillary wedge pressure (PCWP), are poor predictors of "volume responsiveness", which is the cardiovascular response (i.e. changes in preload) to intravascular volume expansion with IV fluid. However, dynamic parameters such as variation in pulse pressure or stroke volume, are highly predictive of volume responsiveness. While data on pulse pressure variation are primarily derived from non-pregnant, mechanically ventilated individuals, a small case series demonstrated that pulse pressure variation accurately reflects volume responsiveness in pregnant women undergoing cesarean delivery under regional anesthesia. Additionally, data from the trauma literature have also demonstrated pulse pressure to represent an accurate surrogate of stroke volume and marker of central hypovolemia. Covertino et al. reported a direct relationship between pulse pressure and central volume reductions without any difference in mean arterial pressure. As such, pulse pressure may serve as a better maker of central hypovolemia than blood pressure alone. Therefore, pulse pressure may better predict low maternal intravascular volume and serve as a marker for post-epidural FHR changes.
Pregnancy itself is associated with alterations in blood pressure with decreased vascular tone and widening of the pulse pressure. Normal pulse pressure and variations in pregnancy are poorly described. However, in otherwise healthy non-pregnant adults, stroke volume is approximately 1.7 times the pulse pressure. Given that the stroke volume in a term pregnancy is approximated to be 100 mL/min, a normal pulse pressure in pregnancy should be approximately 60 mmHg. Therefore, a level of 45 mmHg has been proposed to define a low pulse pressure in pregnancy.
Notably, no prospective studies have evaluated a risk-factor based approach, namely the use of maternal volume status, to guide the volume of the IV fluid bolus administered prior to neuraxial anesthesia. The investigators hypothesize that in individuals with narrow pulse pressure, an increased IV fluid bolus will reduce the rate of post-epidural FHR changes. While pulse pressure variation has been best characterized as a marker of fluid responsiveness in previously healthy critically ill patients, this parameter is only readily obtained through use of an automated device (FloTrac/Vigileo system, Edwards Lifesciences, Irvine, CA) that requires an arterial line. Furthermore, pulse pressure variation has primarily been assessed in mechanically ventilated patients, which is rare in the obstetric setting. Therefore, based on the preliminary data by Miller et al., the investigators plan to use pulse pressure (and not pulse pressure variation) as a marker of intravascular volume this study with a cut point of 45 mmHg to define low pulse pressure. Given that previous studies have used IV fluid preload doses ranging from 500-1500 mL, the IV fluid dosing regimens that will be used in this study represent variations in the standard of care. A practical study design is proposed using current practice patterns for a low risk intervention in a low risk population.
Study Design:
Prospective Randomized Controlled Trial
Study Protocol:
Women meeting eligibility criteria will be recruited and randomized in a 1:1 ratio into two study groups: standard IV fluid bolus prior to epidural placement (500 mL Lactated Ringers) or "volume replacement" IV fluid bolus of 1500mL Lactated Ringers. IV fluid boluses will be infused over 30 minutes and administered within 1 hour of epidural placement. A third group will also be recruited as a control, which will include women with a pulse pressure > 45 on admission (and otherwise meet the aforementioned inclusion/exclusion criteria). The control group will receive the standard preload bolus of 500 mL prior to epidural placement.
This is a practical study using standard clinical practice methods to assess vital signs. Maternal vital signs (blood pressure, heart rate) will be collected in the left lateral recumbent position after an initial 5 minute period without activity. Automated devices will be used to assess blood pressure and pulse pressure at the following times: on admission, immediately prior to infusion of IV fluid bolus in preparation for epidural placement, immediately following IV fluid bolus infusion, at epidural test dose (T=0), every 5 minutes for 30 minutes (T=0 to T=30), and then every 10 minutes for the next 30 minutes (T=30 to T=60).
The chart will be abstracted to identify changes in the FHR and interventions. Continuous external (or internal, if placed for typical obstetric indications), fetal monitoring will be performed before and after epidural placement as is standard on our L\&D unit. Treatment of hypotension with administration of vasopressors or additional IV fluid boluses along with the treatment of FHR abnormalities (maternal position changes, supplemental oxygen administration, tocolytic use, cessation of oxytocin) will be recorded. Operative delivery for non-reassuring fetal status in the 60 minutes after epidural placement will be recorded. Additionally, maternal demographic and medical/obstetric data, maternal and neonatal delivery and outcome data will be recorded.
The technique for epidural placement and dosing will be standardized as follows. Epidural dosing will consist of 5 mL of 0.125% bupivicane with 10 mcg/mL of fentanyl. This standard bolus dose will be administered and levels of sensory block and numeric patient pain scores will be recorded. If patients have not achieved a pain score of 4 or less at 15 minutes after the epidural bolus, an additional bolus will be administered to achieve appropriate pain control. The volume of additional epidural bolus will be recorded.
Two independent obstetricians blinded to the randomization group and delivery outcome will interpret the FHR tracing for one hour before and after epidural placement. The FHR tracings will be divided into 15 minute epochs and categorized using the standard ACOG categories: I, II and III. Additional information including FHR baseline, FHR variability, and the presence or absence of accelerations or decelerations will be recorded for each 15min epoch. Discrepancies between the tracing interpretations will be reviewed by a third obstetrician for development of a consensus interpretation.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Standard IV Preload | No intervention | –Patients in this arm will receive 500mL of Lactated Ringer's solution, which is the standard IV fluid preload used on Labor and Delivery at MetroHealth Medical Center |
| Volume Replacement IV Preload | Experimental | Drug: Lactated Ringer'sPatients in this arm will receive 1500mL of Lactated Ringer's solution |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (8 listed)
- Singleton pregnancy with gestational age ≥ 35 weeks
- Admission for delivery
- Age 18 or older
- Desires neuraxial analgesia in labor
- No exclusion criteria
Key exclusion criteria (12 listed)
- Multiple gestation
- Intrauterine growth restriction
- Hypertensive disorders (gestational hypertension, chronic hypertension, and preeclampsia/eclampsia)
- Gestational or pregestational diabetes mellitus
- Substance abuse
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Lactated Ringer'sAlso: Ringer's Lactate1500 cc of IV Fluid (crystalloid) used for preload prior to epidural administration in the treatment arm. Control arm receives 500 cc. | Drug | Volume Replacement IV Preload |
Primary outcome
Incidence of New-onset Category II or III Fetal Heart Rate Tracings
Time frame: First 60 minutes following epidural placement
Each fetal heart rate tracing was evaluated in 15 min increments from the completion of epidural placement and initial dose administration. ACOG Category I, II, and III was assigned to each 15 min increment.
3 secondary outcomes
New Onset Hypotension (>20% Decrease in Systolic and/or Diastolic Blood Pressure)
Time frame: First 60 minutes following epidural placement
Interventions to Correct Maternal Hypotension or Fetal Heart Rate Abnormalities (Position Change, Supplemental Oxygen, Vasopressor Support, Emergent Operative Delivery)
Time frame: First 60 minutes following epidural placement
Adverse Events (Pulmonary Edema)
Time frame: Duration of intrapartum course
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jul 2018.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Background: PubMed 21553556Osterman MJ, Martin JA. Epidural and spinal anesthesia use during labor: 27-state reporting area, 2008. Natl Vital Stat Rep. 2011 Apr 6;59(5):1-13, 16.
- Background: PubMed 16129992Bucklin BA, Hawkins JL, Anderson JR, Ullrich FA. Obstetric anesthesia workforce survey: twenty-year update. Anesthesiology. 2005 Sep;103(3):645-53. doi: 10.1097/00000542-200509000-00030. No abstract available.
- Background: PubMed 22161362Anim-Somuah M, Smyth RM, Jones L. Epidural versus non-epidural or no analgesia in labour. Cochrane Database Syst Rev. 2011 Dec 7;(12):CD000331. doi: 10.1002/14651858.CD000331.pub3.
- Background: PubMed 719463Collins KM, Bevan DR, Beard RW. Fluid loading to reduce abnormalities of fetal heart rate and maternal hypotension during epidural analgesia in labour. Br Med J. 1978 Nov 25;2(6150):1460-1. doi: 10.1136/bmj.2.6150.1460.
- Background: PubMed 10992845Kinsella SM, Pirlet M, Mills MS, Tuckey JP, Thomas TA. Randomized study of intravenous fluid preload before epidural analgesia during labour. Br J Anaesth. 2000 Aug;85(2):311-3. doi: 10.1093/bja/85.2.311.
- Background: PubMed 15321453Kubli M, Shennan AH, Seed PT, O'Sullivan G. A randomised controlled trial of fluid pre-loading before low dose epidural analgesia for labour. Int J Obstet Anesth. 2003 Oct;12(4):256-60. doi: 10.1016/S0959-289X(03)00071-2.
- Background: PubMed 8831313Nielsen PE, Erickson JR, Abouleish EI, Perriatt S, Sheppard C. Fetal heart rate changes after intrathecal sufentanil or epidural bupivacaine for labor analgesia: incidence and clinical significance. Anesth Analg. 1996 Oct;83(4):742-6. doi: 10.1097/00000539-199610000-00014.
- Background: PubMed 15321239Paech MJ, Godkin R, Webster S. Complications of obstetric epidural analgesia and anaesthesia: a prospective analysis of 10,995 cases. Int J Obstet Anesth. 1998 Jan;7(1):5-11. doi: 10.1016/s0959-289x(98)80021-6.
- Background: PubMed 20395896Wolfler A, Salvo I, Sortino G, Bonati F, Izzo F. Epidural analgesia with ropivacaine and sufentanil is associated with transient fetal heart rate changes. Minerva Anestesiol. 2010 May;76(5):340-5.
- Background: PubMed 15494990Hofmeyr G, Cyna A, Middleton P. Prophylactic intravenous preloading for regional analgesia in labour. Cochrane Database Syst Rev. 2004 Oct 18;2004(4):CD000175. doi: 10.1002/14651858.CD000175.pub2.
- Background: PubMed 15935647Gaiser RR, McHugh M, Cheek TG, Gutsche BB. Predicting prolonged fetal heart rate deceleration following intrathecal fentanyl/bupivacaine. Int J Obstet Anesth. 2005 Jul;14(3):208-11. doi: 10.1016/j.ijoa.2004.12.010.
- Background: PubMed 18400139Nicolet J, Miller A, Kaufman I, Guertin MC, Deschamps A. Maternal factors implicated in fetal bradycardia after combined spinal epidural for labour pain. Eur J Anaesthesiol. 2008 Sep;25(9):721-5. doi: 10.1017/S0265021508004183. Epub 2008 Apr 10.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Justin R Lappen, MD principal investigator
MetroHealth Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Lactated Ringer's in people with Fetus or Neonate Affected by Maternal Epidural Anesthesia During Labor and Delivery, run by MetroHealth Medical Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Jul 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 8 Jun 2018). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of New-onset Category II or III Fetal Heart Rate Tracings (time frame: First 60 minutes following epidural placement). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02565485, which also lists 23 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jul 2018.